SCHEDULE 13G: Cormorant Asset Management Discloses 9.99% Stake in KALA BIO, Inc.

Cormorant Asset Management, LP and Bihua Chen have disclosed a 9.99% beneficial ownership stake in KALA BIO, Inc., totaling 609,027 shares of common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen (collectively, "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership of KALA BIO, Inc. common stock.
• The Reporting Persons collectively own 609,027 shares of KALA BIO, Inc. common stock.
• This ownership represents 9.99% of the Issuer's outstanding common stock.
• The reported holdings include 603,027 shares of common stock and 6,000 shares issuable upon conversion of Series I Convertible Non-Redeemable Preferred Stock.
• Conversion of Series I Preferred Stock is limited to prevent beneficial ownership exceeding 9.99% of outstanding common stock.
• The Reporting Persons could potentially receive up to an additional 328,600 shares of common stock upon conversion of Series I Preferred Stock, subject to the 9.99% limitation.
• The percentage of class is calculated based on KALA BIO, Inc.'s Current Report on Form 8-K filed December 30, 2024, which stated an expected 6,091,182 shares of common stock outstanding after a private placement closing on December 31, 2024.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement from the company itself. The presence of a significant institutional investor can be seen positively, but the filing itself is purely informational.

Positives

• A significant institutional investor, Cormorant Asset Management, has taken a substantial stake in KALA BIO, Inc., potentially signaling confidence in the company's future.
• The investment includes both common stock and convertible preferred stock, indicating a flexible investment strategy.

Negatives

• The 9.99% conversion limitation on Series I Preferred Stock restricts the immediate increase in the Reporting Persons' direct common stock ownership beyond this threshold.

Risks

• The beneficial ownership percentage is calculated based on an expected share count from a private placement, which could be subject to change if the private placement terms or closing are altered.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the company itself. It indicates the potential for the Reporting Persons to convert additional Series I Preferred Stock into common stock, up to a 9.99% beneficial ownership cap.

Management Comments

• Bihua Chen, Managing Member of Cormorant Asset Management, LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

The filing of a Schedule 13G by an investment adviser like Cormorant Asset Management indicates active institutional investment in the biotechnology or pharmaceutical sector, where KALA BIO, Inc. likely operates. Such filings are common for institutional investors taking significant, but passive, stakes in public companies.

Comparison to Industry Standards

• The 9.99% beneficial ownership stake is a significant position for an institutional investor, often chosen to avoid triggering more stringent reporting requirements (e.g., Schedule 13D, which implies intent to influence control) or certain corporate governance thresholds.
• Cormorant Asset Management is a known healthcare-focused investment firm, and their investment in KALA BIO, Inc. aligns with their typical investment strategy in the biotech industry.
• The use of convertible preferred stock with a conversion cap is a common strategy for institutional investors to gain exposure while managing regulatory reporting obligations and potential dilution impacts.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 9.99% stake could be viewed positively, potentially signaling confidence in the company. The conversion limitation ensures that the investor's stake remains below a certain threshold, which might alleviate concerns about immediate control changes.

Next Steps

• The Reporting Persons may convert additional Series I Preferred Stock into common stock, subject to the 9.99% beneficial ownership limitation.

Key Dates

Keywords

KALA BIO, Cormorant Asset Management, Bihua Chen, Schedule 13G, beneficial ownership, common stock, Series I Preferred Stock, institutional investor, SEC filing, equity stake